Drug · CHEMBL902
FAMOTIDINE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. FAMOTIDINE. Drugs and targets, record CHEMBL902. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL902
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Brand names
Famotidine component of duexis, Famotidine component of pepcid complete, Famotidine preservative free, Famotidine preservative free (pharmacy bulk), Fluxid, Gaster, Pepcid, Pepcid ac, Pepcid ac (geltab), Pepcid preservative free, Pepcid rpd, Pepcidine
- ChEMBL
- Other names
- Amfamox, Fadul, Famodil, Famosan, Famotidina, Famoxal, Ganor, Gastridin, Gastropen, L 643341, Lecedil, MK-208, Motiax, Muclox, NSC-757810, Pepcidac, Pepdine, Pepdul, YM-11170
- ChEMBL
- Open Targets' highest stage
- Approval, for 10 of its 31 diseases, from ATC, DailyMed and TTD
- Open Targets
Targets1
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| HRH2 | Histamine H2 receptor | Histamine H2 receptor antagonist | ANTAGONIST | https://conductscience.org/library/genes/3274 |
Source ChEMBL
Diseases31
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 31Source Open Targets
See all 31 diseasesTrials106
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT00450216 | Efficacy and Safety Study of HZT-501 in Subjects Requiring Nonsteroidal Anti-Inflammatory Drug (NSAID) Treatment | Phase 3 | 906 | 2011-06-21 | famotidine | Its name | ClinicalTrials.gov |
| NCT00450658 | Efficacy and Safety Study of HZT-501 in Reducing the Risk of Ibuprofen-associated Ulcers | Phase 3 | 627 | 2011-06-21 | famotidine | Its name | ClinicalTrials.gov |
| NCT01499368 | A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess and Compare to the Efficacy and Safety of Lafutidine, Famotidine and Omeprazole-referenced in Korean Erosive Esophagitis Patients | Phase 3 | 495 | 2020-09-16 | famotidine | Its name | ClinicalTrials.gov |
| NCT02418312 | Efficacy of H2 Receptor Antagonist in Prevention of Thienopyridine-related Peptic Ulcer | 228 | 2019-03-11 | famotidine | Its name | ClinicalTrials.gov | |
| NCT02473042 | Intraoperative Acupoint Stimulation to Prevent Post-Operative Nausea and Vomiting (PONV) | 188 | 2025-12-05 | famotidine | Its name | ClinicalTrials.gov | |
| NCT00613106 | Double-Blind Follow-on Safety Study of HZT-501 (Ibuprofen 800 mg/Famotidine 26.6 mg) in Subjects Who Have Completed Participation in HZ-CA-301 (NCT00450658) or HZ-CA-303 (NCT00450216) | Phase 3 | 179 | 2011-06-17 | famotidine | Its name | ClinicalTrials.gov |
| NCT04862585 | Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel | Phase 2/3 | 130 | 2025-08-20 | famotidine | Its name | ClinicalTrials.gov |
| NCT02551744 | Proton Pump Inhibitor Versus Histamine-2 Receptor Antagonist for the Prevention of Recurrent Peptic Ulcers | 101 | 2019-08-08 | famotidine | Its name | ClinicalTrials.gov | |
| NCT06154226 | Prevention of Post-Cardiac Surgery Acute Kidney Injury by Proton Pump Inhibitor | Phase 2 | 100 | 2026-03-10 | famotidine | Its name | ClinicalTrials.gov |
| NCT00984815 | Safety Study of HZT-501 in Patients Who Require Long-Term Daily Non-steroidal Anti-inflammatory Drug Treatment | Phase 3 | 86 | 2013-07-25 | famotidine | Its name | ClinicalTrials.gov |
1 to 10 of 106
See all 106 trialsComparisons in its trials58
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| HZT-501 vs Ibuprofen: serious adverse events | 22 of 607 | 13 of 299 | 906 | NCT00450216 | Trial comparisons |
| HZT-501 vs Ibuprofen: Number of Participants Who Develop Endoscopically-diagnosed Duodenal Ulcers During the 24-week Treatment Period. | 8 of 550 | 14 of 262 | 812 | NCT00450216 | Trial comparisons |
| HZT-501 vs Ibuprofen: Number of Participants Who Develop Endoscopically-diagnosed Gastric Ulcers | 55 of 550 | 52 of 262 | 812 | NCT00450216 | Trial comparisons |
| HZT-501 vs Ibuprofen: Number of Participants Who Develop Endoscopically-diagnosed Upper Gastrointestinal (UGI) Ulcers During the 24-week Treatment Period. | 63 of 550 | 61 of 262 | 812 | NCT00450216 | Trial comparisons |
| HZT-501 vs Ibuprofen: The Incidence Rate of NSAID-associated Serious Gastrointestinal Complications. | 0 of 415 | 0 of 212 | 627 | NCT00450658 | Trial comparisons |
| HZT-501 vs Ibuprofen: serious adverse events | 11 of 415 | 4 of 212 | 627 | NCT00450658 | Trial comparisons |
| HZT-501 vs Ibuprofen: Number of Subjects Who Develop Endoscopically-diagnosed Upper Gastrointestinal Ulcers Confirmed by Endoscopy. | 40 of 380 | 38 of 190 | 570 | NCT00450658 | Trial comparisons |
| HZT-501 vs Ibuprofen: Number of Subjects Who Develop Endoscopically-diagnosed Duodenal Ulcers During the 24-week Treatment Period. | 3 of 380 | 9 of 190 | 570 | NCT00450658 | Trial comparisons |
| HZT-501 vs Ibuprofen: Number of Subjects Who Develop Endoscopically-diagnosed Gastric Ulcers During the 24-week Treatment Period. | 37 of 380 | 34 of 190 | 570 | NCT00450658 | Trial comparisons |
| Histamine-2 Receptor Antagonist Group vs Placebo Group: Number of Participants With Healed Peptic Ulcer | 106 of 114 | 101 of 114 | 228 | NCT02418312 | Trial comparisons |
1 to 10 of 58
See all 58 comparisons in its trialsPapers from its trials23
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL902
GET https://conductscience.org/api/drugs/v1/CHEMBL902/diseases?page=2